## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.1% below STRENGTH zone (3.0-6.0%); PEG 2.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($111.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Invesco S&P International Developed Low Volatility ETF $IDLV Stock Position Lowered by CW Advisors LLC**
- Source: Defense World | 20251208T090900 | Neutral | Relevance: 73%
-  CW Advisors LLC significantly reduced its holdings in the Invesco S&P International Developed Low Volatility ETF ($IDLV) by 37.3% in the second quarter, selling over 22,000 shares. Despite this, other firms like Richmond Investment Services LLC, Del Sette Capital Management LLC, Bell Investment Advisors Inc, Cetera Investment Advisers, and PFG Advisors have either increased their positions or initiated new ones in the ETF during the same period. The article also provides a brief profile and price performance data for the Invesco S&P International Developed Low Volatility ETF.

**2. Elanco Animal Health (NYSE:ELAN) Coverage Initiated by Analysts at Barclays**
- Source: MarketBeat | 20251209T140958 | Neutral | Relevance: 63%
-  Barclays initiated coverage on Elanco Animal Health (NYSE:ELAN) with an "overweight" rating and a $30 price target, representing a potential 38.34% upside. This follows strong Q3 results where the company beat EPS and revenue estimates, and provided positive FY2025 guidance. Other analysts also have a "Moderate Buy" consensus rating for Elanco and an average target price of $22.78.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |
| 2025-11-21 | Keybanc | $0 | $0 | 0% |
| 2025-11-18 | Stifel | $130 | $140 | -7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |
| 2025-11-21 | Keybanc | init | Sector Weight |
| 2025-11-18 | Stifel | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 21.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.19 elevated, pricing in significant growth expectations. Forward P/E 17.4x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $52.3B |
| Beta | 0.97 |
| 52W Range | $115.25 - $181.85 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.19 |
| Forward P/E | 17.4 |
| Current P/E | 18.6 |
| YoY Growth | 7.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 7.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.79x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.14% (CS: 8) | Weak |
| RSI_14 | 36.3 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 0.891x | Below |
| vs SMA200 | 0.785x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $118.07
- **Stop Loss:** $111.45 (5.6% risk)
- **Target:** $124.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 75
- **Position Value:** $8,855.25
- **Portfolio %:** 8.86%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*